SE
SE
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
0
$0
Total Volume
$0
43 transactions
Net Activity
+$0
Net buying
Sentiment Rating
Neutral / BalancedCEO Conviction Index
No Recent Signal
Key Drivers
- •Balanced trading volume with net neutral buying and selling activity.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
SE has an insider buy conviction of 50%, compared to the Unknown sector buy average of 50%. SE ranks #11 in insider activity out of 261 tracked companies in its industry.
Multiple Insiders
S - Sale Insiders
$0 total
Over the last 90 days, corporate insiders at SE (SE) engaged in a total of 43 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 0 were sales. The total volume of insider trading reached $0.
The net insider activity for SE shows a net buying bias of $0. This activity represents a 50% buy ratio, suggesting that insiders are currently neutral on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (S - Sale Insiders), who traded 1.13M shares valued at $0 on Sep 23, 2026.
Quick Actions
Related News & Analyst Reports
Read original insights and educational research covering SE and the Unknown sector.
The AI Circular Valuation Bubble: Inside the Venture-Cloud Loop
An in-depth investigation into how technology giants and AI startups engage in circular capital flows, investing venture capital in exchange for cloud services and hardware, creating a closed-loop economy that artificially inflates valuations.
The Biotech Executive Playbook: Tracking Clinical Phase SEC Filings
An empirical study on how clinical-stage biotech executives execute Form 4 open-market purchases ahead of trial data releases, outlining the regulatory gaps and alpha potential of clinical insider tracking.
The Spinoff Separation: Tracking Post-Spinoff Executive Ownership Trends
An investigation of corporate spinoffs, showing how executive equity allocations and post-separation insider transactions signal parent and subsidiary performance trajectories.
Lock-up Expiration Frontrunning: How Venture Funds Manage Large Block Trades
When lock-up periods expire, venture funds use block trades, 10b-18 programs, and coordinated secondary offerings to exit large positions. This report reveals the strategies that minimize price impact, and how retail investors can track them.
Deciphering Form 5 Filings: Uncovering Annual Insider Gift Trades
A comprehensive guide to SEC Form 5 filings, explaining how annual reports of gift shares, stock options, and non-open-market transactions signal insider sentiment.
The Quant Guide: Backtesting SEC Form 4 Cluster Buys for Alpha
A rigorous quantitative backtest of SEC Form 4 cluster buying activity, demonstrating how to isolate signal from noise and build portfolios that consistently outperform benchmarks.
FAQs About SE Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for SE.